Emgality Injection, Solution
Product Images NDC 0002-3115

Product Visual Gallery

This gallery contains 39 technical images submitted to the FDA as part of the official labeling for Emgality (NDC 0002-3115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Carton – Emgality Prefilled Syringe 100 mg (Emgality Carton 100mg Pfs 045 01)

Packaging label for Emgality (galcanezumab-gnlm) 100 mg/mL injection, supplied as 3 x 100 mg/mL single-dose prefilled syringes. The label indicates the product is for subcutaneous use only, single-dose only, and prescription use. It features the Eli Lilly and Company logo and instructions that all 3 syringes must be administered to receive the 300 mg dose.*

FDA Label Image

Package Carton – Emgality Autoinjector 120 mg (Emgality Carton 120mg Ai 039 02)

Packaging label for Emgality (galcanezumab-gnlm) 120 mg/mL injection, a single-dose prefilled pen. The label shows the product name, strength, dosage form, and an image of the prefilled pen. It includes usage instructions indicating subcutaneous use only, single-dose only, and prescription Rx only status. Labeler is Eli Lilly and Company.*

FDA Label Image

Package Carton – Emgality Prefilled Syringe 120 mg (Emgality Carton 120mg Pfs 043 02)

Packaging label for Emgality (galcanezumab-gnlm) 120 mg/mL injection. The label shows a single-dose prefilled syringe with a 120 mg/mL strength. It is indicated for subcutaneous use only, single-dose only, and prescription use. Labeler is Eli Lilly and Company. The NDC number 0002-2377-11 is printed on the label.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 1 V1)

An illustration of a medical injection device, featuring a clear cylindrical barrel with a plunger. The plunger has a red handle, and the base around the barrel has a textured grip area. This image likely represents a prefilled syringe used for injection.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 2 V1)

An instructional diagram of a syringe labeled with parts including Thumb Pad, Coral Plunger Rod, Finger Grips, Gray Syringe Plunger, Syringe Body with Medicine, Needle, and Needle Cap. The syringe is shown with the needle cap removed below the needle.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 3 V1)

An instructional illustration showing a syringe-like device with a plunger. An arrow points to the central window area of the device, highlighting it for emphasis. The image appears to demonstrate a specific feature or step related to the device's use, possibly for an injection. No text or branding is visible.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 4 V1)

An instructional illustration showing a pair of hands preparing an injection. One hand holds a syringe with the needle inserted into a vial or cartridge held by the other hand. A red arrow points to the right indicating the direction of pulling or withdrawing the solution into the syringe. Likely related to the preparation of galcanezumab-gnlm injection solution.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 5 V1)

An instructional illustration showing how to inject a solution subcutaneously at a 45-degree angle. The image depicts hands administering an injection with the needle positioned between 45 and 90 degrees relative to the skin surface.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 6 V1)

An instructional illustration showing a person administering an injection with a syringe into their forearm. A hand holds the syringe with an arrow indicating the direction of injection into the skin.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 7 V1)

An instructional illustration showing a hand holding a syringe used for injection of galcanezumab-gnlm. Labels point to the 'Coral plunger rod' and the 'Gray syringe plunger', identifying parts of the syringe mechanism.*

FDA Label Image

Figure (Emgality Ifu 100mg Pfs 8 V1)

An instructional illustration showing a hand holding a prefilled injection syringe with a red safety cap, positioned above a sharps disposal container. The image demonstrates proper disposal of the syringe into the container, related to the galcanezumab-gnlm injection solution product by Eli Lilly and Company.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 1 V1)

Illustration of a prefilled syringe or injection device for administration of galcanezumab-gnlm injection solution. The device features a transparent barrel and a rounded plunger with a teal push-button end.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 2 V1)

An instructional illustration of a syringe for injection, labeled with parts including thumb pad, teal plunger rod, finger grips, gray syringe plunger, syringe body with medicine, needle, and needle cap.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 3 V1)

An instructional illustration showing a syringe-like medical device labeled with an arrow pointing to the area where the expiration date is located on the device. The device consists of a plunger, a barrel with a visible window, and a needle end typically used for injections.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 4 V1)

An instructional illustration showing hands preparing an injection syringe. One hand holds the syringe while the other removes a protective cap from the needle, indicated by a red arrow to guide the action.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 5 V1)

An instructional illustration showing a hand injecting a solution at a 45-degree angle into the skin of the other hand's finger, indicating the proper injection angle for administration.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 6 V1)

An instructional illustration showing the administration of an injection. A hand holds a syringe oriented toward the skin of the opposite arm, with a red arrow indicating the downward motion to inject the solution subcutaneously.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 7 V1)

An instructional illustration showing a hand holding a syringe for injection. The syringe has labeled parts including a teal plunger rod and a gray syringe plunger. This relates to the galcanezumab-gnlm injection, solution dosage form by Eli Lilly and Company.*

FDA Label Image

Figure (Emgality Ifu 120mg Pfs 8 V1)

Illustration showing a hand holding a syringe with a needle being inserted into a red sharps disposal container with a gray lid, demonstrating proper disposal of an injection device.*

FDA Label Image

Figure (Emgality Ifu Ai 1 V1)

An instructional illustration showing a prefilled autoinjector pen containing a solution for injection. The pen is labeled with partial icons and a textured grip area, typical for drug delivery devices for subcutaneous administration. The labeler is Eli Lilly and Company, related to injections of galcanezumab-gnlm at strengths of 100 mg/mL or 120 mg/mL.*

FDA Label Image

Figure (Emgality Ifu Ai 2 V1)

An instructional diagram of a galcanezumab-gnlm injection pen showing labeled parts including the teal injection button at the top, lock ring with lock/unlock symbols, the medicine inside the transparent shaft, a clear base, and a removable base cap covering the needle end at the bottom.*

FDA Label Image

Figure (Emgality Ifu Ai 3 V2)

An illustration of a galcanezumab-gnlm injection solution pen showing the location of the expiration date on the device. The image highlights the area on the pen where the expiration date is printed or labeled, indicated by a red oval and arrow.*

FDA Label Image

Figure (Emgality Ifu Ai 4 V1)

An instructional illustration showing a hand holding a galcanezumab-gnlm injection pen with a close-up inset of the pen's lock mechanism, demonstrating how to unlock the pen by rotating the bottom part before use.*

FDA Label Image

Figure (Emgality Ifu Ai 5 V1)

An instructional illustration showing the preparation of an injection syringe. The main image depicts hands holding a syringe with a cap being removed. An inset shows a close-up of twisting or turning the cap off the syringe, indicated by a red arrow, as a preparatory step before injection.*

FDA Label Image

Figure (Emgality Ifu Ai 6 V1)

An instructional illustration showing a hand holding an injection pen close to the skin, indicating to click and press the pen for 10 seconds. The image includes a red arrow pointing in the direction of the injection site, demonstrating the proper technique to administer the dose of galcanezumab-gnlm injection solution.*

FDA Label Image

Figure (Emgality Ifu Ai 7 V1)

An instructional illustration showing a close-up of an injection device with a gray plunger. The text explains that the injection is complete when the gray plunger becomes visible, indicating full administration of the dose.*

FDA Label Image

Figure (Emgality Ifu Ai 8 V1)

Instructional illustration showing a hand holding an injection pen above a sharps disposal container, demonstrating proper disposal of a used injection device for galcanezumab-gnlm injection, solution.*

FDA Label Image

Figure (Emgality Ifu Inj Sites V2)

An instructional illustration showing recommended injection sites on the human body. Highlighted areas include the abdomen, thigh, buttock, and back of the arm, indicated on front and back views of a standing human figure.*

FDA Label Image

Figure (Emgality Ifu Lock V1)

FDA Label Image

Figure (Emgality Ifu Unlock V1)

FDA Label Image

Figure 1 (Emgality Pi F1 V1)

A line graph showing mean change from baseline in migraine headache days over six months. The graph compares two groups: one treated with Emgality (galcanezumab-gnlm) 120 mg, and a placebo group. The Emgality group shows a greater reduction in migraine headache days compared to placebo, with error bars indicating variability.*

FDA Label Image

Figure 2 (Emgality Pi F2 V1)

Line graph depicting mean change from baseline in migraine headache days over six months. The graph compares two groups: placebo and Emgality 120 mg, with migraine days plotted on the vertical axis and time (baseline to month 6) on the horizontal axis. Data points include error bars indicating variability.*

FDA Label Image

Figure 3 (Emgality Pi F3 V1)

A bar chart comparing the percentage of patients with fewer migraine days per month between a placebo group (N=425) and a group treated with EMGALITY 120 mg (N=210). The x-axis shows ranges of fewer migraine days per month, while the y-axis shows the percentage of patients. EMGALITY-treated patients generally show higher percentages in greater reductions of migraine days compared to placebo.*

FDA Label Image

Figure 4 (Emgality Pi F4 V1)

A bar graph comparing the percentage of patients experiencing fewer migraine days per month between placebo (N=450) and EMGALITY 120 mg (N=226). The x-axis categorizes the reduction in migraine days, and the y-axis shows the percentage of patients. EMGALITY 120 mg data is represented in black bars, placebo in white.*

FDA Label Image

Figure 6 (Emgality Pi F5 V1)

A line graph showing the mean change from baseline in migraine headache days over three months. The graph compares placebo and Emgality 120 mg, with Emgality showing a greater reduction in migraine headache days compared to placebo. Error bars indicate variability at each time point: baseline, month 1, month 2, and month 3.*

FDA Label Image

Figure 6 (Emgality Pi F6 V1)

A bar chart comparing the percentage of patients with fewer migraine days per month for placebo versus Emgality 120 mg (galcanezumab-gnlm) injection. The x-axis categorizes ranges of reduced migraine days, and the y-axis shows the percentage of patients, illustrating differences in efficacy between placebo and Emgality groups.*

FDA Label Image

Figure 7 (Emgality Pi F7 V2)

A line graph comparing the LS Mean Change from baseline (BL) with standard error (SE) over three weeks between placebo and EMGALITY 300 mg treatment groups. The y-axis indicates improvement, while the x-axis shows baseline and weeks 1 through 3. EMGALITY 300 mg shows greater improvement compared to placebo across the study period.*

FDA Label Image

Figure 8 (Emgality Pi F8 V2)

A bar chart comparing the percentage reduction of cluster headache attacks per week between placebo (N=57) and Emgality 300 mg (N=49). The x-axis shows categories of percent reduction ranges (>75 to 100%, >50 to 75%, >25 to 50%, >0 to 25%, and no change or more attacks). The y-axis indicates the percentage of patients. Black bars represent Emgality 300 mg, and white bars represent placebo.*

FDA Label Image

Figure (Emgality Qr V1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.